CellCentric and Cancer Research Technology Ltd (CRT) have announced that they have begun an anti-cancer co-development programme.
The programme of two phases aims to initially validate CellCentric’s epigenetic-related lead cancer target, and subsequently develop monoclonal antibody therapeutic products.
Both parties will share the costs and rewards of the collaboration which may be followed by the co-development of other targets identified by CellCentric.
CellCentric’s technology is based on its understanding of epigenetic mechanisms that control cell function and fate.
Many cancers have abnormal epigenetic profiles and by targeting errant epigenetic mechanisms, cancer cells can be selected for destruction.
CellCentric has identified several proteins that influence cell fate and are clear candidates for the development of cancer therapeutics.
Commenting on the news, Dr Will West, CellCentric’s COO said, “Collaborating with CRT is a very important next step for CellCentric in working towards product development from its epigenetics research platform.”
“Working with a partner of the calibre of CRT demonstrates great confidence in the potential of CellCentric’s epigenetics discovery base.”
“It is encouraging to see that, in such a short time, we have progressed our epigenetics research to a stage where collaboration is possible.”